Beyondspring INC

BeyondSpring Inc. announces leadership changes effective July 1, 2026, with Min Qiu appointed CEO and Na Li as CFO, to focus on the DUBLIN-4 Phase 3 program.

BeyondSpring Inc. announced its first-quarter 2026 financial results, highlighting advancements in its Plinabulin and SEED Therapeutics programs, with a focus on enhancing cancer therapies.

BeyondSpring Inc. announced its full-year 2025 financial results, highlighting significant clinical progress for Plinabulin and strategic advancements for SEED Therapeutics.

BeyondSpring Inc. announced a delay in the second closings of its previously disclosed sale of Series A-1 Preferred Shares of SEED Therapeutics Inc. until the first half of 2026.

BeyondSpring Inc. announced the closing of a private placement, raising $2.0 million through the sale of 800,000 ordinary shares to Ray Beauty Group Limited.

BeyondSpring Inc. announced its third-quarter 2025 financial results, highlighting positive clinical data for Plinabulin and significant milestones for its co-founded entity, SEED Therapeutics.

BeyondSpring Inc. reported a significantly reduced consolidated net loss for the first nine months of 2025, driven by a gain from the partial sale of its SEED Therapeutics subsidiary, while advancing its lead asset Plinabulin.

BeyondSpring Inc. reports improved financial health and strategic focus on its lead asset Plinabulin after divesting a portion of its SEED Therapeutics stake.

BeyondSpring Inc. reports a net income of $1.2 million for Q1 2025, driven by a gain from the sale of SEED Therapeutics shares, while continuing to advance its Plinabulin pipeline.

BeyondSpring Inc. reported a net loss of $14.2 million for 2025, while advancing its lead asset Plinabulin in NSCLC and its SEED Therapeutics' TPD platform into clinical studies.

BeyondSpring Inc. announces its FY 2024 results, emphasizing the statistically significant overall survival benefit of Plinabulin in combination with docetaxel for secondand third-line NSCLC treatment.

BeyondSpring Inc. reports the grant of 100,000 stock options to Director Jiangwen Majeti, exercisable at $1.75 per share.

BeyondSpring Inc. reports the grant of 100,000 stock options to CEO Min Qiu, exercisable at $1.75, with vesting over four years.

CEO Lan Huang transferred 260,582 ordinary shares via a gift transaction, reallocating holdings among family trusts.

BeyondSpring Inc. reports the grant of stock options to Director Matthew Kirkby, with vesting scheduled for April 1, 2027.

BeyondSpring Inc. reports the grant of stock options to Director Patrick Fabbio, exercisable at $1.64 per share.

BeyondSpring Inc. reports the grant of stock options to Director Brendan Delaney, exercisable at $1.64 per share.

BeyondSpring Inc. announces its 2025 Annual Meeting of Shareholders for September 15, 2025, to vote on auditor ratification and other matters.

BeyondSpring Inc. announces its 2025 Annual General Meeting for September 15, 2025, where shareholders will vote on the ratification of CBIZ CPAs P.C. as the independent auditor, following Marcum LLP's resignation.

BeyondSpring co-founders Lan Huang and Linqing Jia filed an amended Schedule 13G disclosing updated beneficial ownership of 14.1% of the company's outstanding shares.

Decheng Capital and its affiliates, including Dr. Xiangmin Cui, report a combined 9.2% beneficial ownership in Beyondspring Inc. as of December 31, 2025.

Decheng Capital and its affiliates, led by Xiangmin Cui, have reported an 11.2% beneficial ownership stake in BeyondSpring Inc. as of June 30, 2025.

BeyondSpring Inc.'s co-founders, Dr. Lan Huang and Mr. Linqing Jia, have filed an amended Schedule 13G/A, disclosing a shared beneficial ownership of 15.01% of the company's ordinary shares as of December 31, 2024, reflecting recent transfers and proxy changes.